Humacyte (NASDAQ:HUMA) Given Buy Rating at Benchmark

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Benchmark in a research report issued to clients and investors on Thursday,Benzinga reports.

A number of other equities research analysts have also recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $13.71.

Humacyte Stock Performance

Shares of NASDAQ:HUMA traded down $0.34 during trading hours on Thursday, reaching $3.06. The stock had a trading volume of 2,061,504 shares, compared to its average volume of 2,275,058. The stock has a market capitalization of $385.13 million, a price-to-earnings ratio of -2.28 and a beta of 1.30. The firm's 50 day moving average is $4.36 and its 200-day moving average is $4.94. Humacyte has a 1 year low of $2.81 and a 1 year high of $9.97.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of HUMA. Endowment Wealth Management Inc. increased its holdings in Humacyte by 3.6% during the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company's stock valued at $526,000 after acquiring an additional 3,590 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Humacyte by 18.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company's stock worth $138,000 after acquiring an additional 4,327 shares in the last quarter. Beacon Pointe Advisors LLC raised its position in Humacyte by 33.3% in the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company's stock valued at $101,000 after purchasing an additional 5,000 shares during the period. Rhumbline Advisers raised its holdings in shares of Humacyte by 4.6% during the 4th quarter. Rhumbline Advisers now owns 114,455 shares of the company's stock valued at $578,000 after buying an additional 5,005 shares during the period. Finally, Teacher Retirement System of Texas lifted its position in shares of Humacyte by 25.3% during the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company's stock worth $132,000 after purchasing an additional 5,293 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.